Spots Global Cancer Trial Database for A Study of T-DXd in Patients With Selected HER2-overexpressing Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of T-DXd in Patients With Selected HER2-overexpressing Tumors
Official Title: A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Patients With Selected HER2-overexpressing Tumors (DESTINY PanTumor03)
Study ID: NCT06271837
Interventions
Study Description
Brief Summary: This is an open-label, multicenter, Phase II study to evaluate the efficacy and safety of trastuzumab deruxtecan for the treatment in locally advanced, unresectable, or metastatic patients with selected HER2 overexpressingsolid tumors which are not eligible for curative therapy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Beijing, , China
Research Site, Changchun, , China
Research Site, Changsha, , China
Research Site, Changzhou, , China
Research Site, Chengdu, , China
Research Site, Chongqing, , China
Research Site, Dongyang, , China
Research Site, Guangzhou, , China
Research Site, Guangzhou, , China
Research Site, Haikou, , China
Research Site, Hangzhou, , China
Research Site, Harbin, , China
Research Site, Hefei, , China
Research Site, Kunming, , China
Research Site, Lishui, , China
Research Site, Nanchang, , China
Research Site, Shanghai, , China
Research Site, Shanghai, , China
Research Site, Shenyang, , China
Research Site, Xuzhou, , China
Research Site, Yinchuan, , China
Research Site, Zhengzhou, , China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
